CHF1535

DRUG2 trials

Sponsors

Chiesi Farmaceutici S.p.A.

Conditions

Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic Obstructive

Phase 3

BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)

CompletedNCT00929851

Chiesi Farmaceutici S.p.A.Pulmonary Disease, Chronic Obstructive

Start: 2009-10-31End: 2012-07-31Updated: 2021-10-29

Phase 4

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

CompletedNCT05097014

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2021-10-28End: 2023-02-24Updated: 2023-03-24

Related Papers

Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial.

2024-10-17

LATE-BREAKING ABSTRACT: Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): An across-trials model-based approach

2016-09-015 citations